Found: 21
Select item for more details and to access through your institution.
Common P-glycoprotein (ABCB1) polymorphisms do not seem to be associated with the risk of rivaroxaban-related bleeding events: Preliminary data.
- Published in:
- Biochemia Medica, 2024, v. 34, n. 2, p. 1, doi. 10.11613/BM.2024.020703
- By:
- Publication type:
- Article
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?
- Published in:
- Genes, 2024, v. 15, n. 5, p. 607, doi. 10.3390/genes15050607
- By:
- Publication type:
- Article
Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy.
- Published in:
- Fundamental & Clinical Pharmacology, 2024, v. 38, n. 2, p. 351, doi. 10.1111/fcp.12958
- By:
- Publication type:
- Article
Plasma Brain-Derived Neurotrophic Factor Levels in First-Episode and Recurrent Major Depression and before and after Bright Light Therapy in Treatment-Resistant Depression.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 9, p. 1425, doi. 10.3390/biom13091425
- By:
- Publication type:
- Article
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 8, p. 1117, doi. 10.1007/s00228-023-03526-z
- By:
- Publication type:
- Article
Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series.
- Published in:
- Pharmacy, 2023, v. 11, n. 1, p. 29, doi. 10.3390/pharmacy11010029
- By:
- Publication type:
- Article
The role of pharmacogenetics as a possible risk factor for rivaroxaban – associated bleeding.
- Published in:
- Cardiologia Croatica, 2022, v. 17, n. 9/10, p. 278, doi. 10.15836/ccar2022.278
- By:
- Publication type:
- Article
Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 9, p. 1461, doi. 10.1111/jcpt.13650
- By:
- Publication type:
- Article
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2190, doi. 10.1111/bcp.15144
- By:
- Publication type:
- Article
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case–control study.
- Published in:
- European Journal of Clinical Pharmacology, 2022, v. 78, n. 2, p. 227, doi. 10.1007/s00228-021-03233-7
- By:
- Publication type:
- Article
Pharmacogenomics – a Promising Tool for Elderly Patients on Polytherapy.
- Published in:
- 2020
- By:
- Publication type:
- Abstract
Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
- Published in:
- Croatian Medical Journal, 2020, v. 61, n. 2, p. 147, doi. 10.3325/cmj.2020.61.147
- By:
- Publication type:
- Article
REMISSION IS NOT ASSOCIATED WITH DRD2 RS1800497 AND DAT1 RS28363170 GENETIC VARIANTS IN MALE SCHIZOPHRENIC PATIENTS AFTER 6-MONTHS MONOTHERAPY WITH OLANZAPINE.
- Published in:
- Psychiatria Danubina, 2020, v. 32, n. 1, p. 84, doi. 10.24869/psyd.2020.84
- By:
- Publication type:
- Article
Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis.
- Published in:
- European Psychiatry, 2019, v. 61, p. 88, doi. 10.1016/j.eurpsy.2019.07.004
- By:
- Publication type:
- Article
INTEGRATION OF COMPLEMENTARY BIOMARKERS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS: RESEARCH PROTOCOL OF A PROSPECTIVE FOLLOW UP STUDY.
- Published in:
- Psychiatria Danubina, 2019, v. 31, n. 2, p. 162, doi. 10.24869/psyd.2019.162
- By:
- Publication type:
- Article
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady‐state disposition of lamotrigine in adults with epilepsy.
- Published in:
- British Journal of Clinical Pharmacology, 2018, v. 84, n. 9, p. 2106, doi. 10.1111/bcp.13646
- By:
- Publication type:
- Article
Dapsone-induced agranulocytosis-possible involvement of low-activity N-acetyltransferase 2.
- Published in:
- Fundamental & Clinical Pharmacology, 2017, v. 31, n. 5, p. 580, doi. 10.1111/fcp.12287
- By:
- Publication type:
- Article
FARMAKOGENOMIKA U PEDIJATRIJSKOJ POPULACIJI.
- Published in:
- Paediatria Croatica, Supplement, 2017, v. 61, p. 184
- By:
- Publication type:
- Article
Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.
- Published in:
- Drug Metabolism & Personalized Therapy, 2017, v. 32, n. 1, p. 11, doi. 10.1515/dmpt-2016-0024
- By:
- Publication type:
- Article
Genetic variants of reduced clopidogrel absorption and platelet reactivity after standard clopidogrel therapy and serial dose tailoring in the NCT02096419 trial: a pharmacogenetic substudy.
- Published in:
- Cardiologia Croatica, 2015, v. 10, n. 9/10, p. 6, doi. 10.15836/ccar.2015.205
- By:
- Publication type:
- Article
Platelet reactivity pattern in a patient with multiple pharmacogenetic factors of reduced clopidogrel efficiency.
- Published in:
- Cardiologia Croatica, 2015, v. 10, n. 9/10, p. 7, doi. 10.15836/ccar.2015.206
- By:
- Publication type:
- Article